Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Time For Independent FDA? COVID-19 Political Pressure Reignites Debate

Executive Summary

The political spotlight on the Food & Drug Administration during the COVID-19 pandemic has renewed the long-standing debate as to whether FDA should be made an independent, Cabinet-level federal agency and freed from direct HHS oversight.

You may also be interested in...



Politics Is US FDA Commissioners’ Biggest Challenge, Ex-Trump Agency Head Hahn Says

In a Pink Sheet interview, Stephen Hahn also discusses the unique risk-benefit calculations that may come into play for the ‘preemptive’ therapeutics he hopes to spearhead in his new position at Flagship Pioneering and his tendency to follow in the career path of another former commissioner, Scott Gottlieb.

Politics Is US FDA Commissioners’ Biggest Challenge, Ex-Trump Agency Head Hahn Says

In a Pink Sheet interview, Stephen Hahn also discusses the unique risk-benefit calculations that may come into play for the preemptive’ therapeutics he hopes to spearhead in his new position at Flagship Pioneering and his tendency to follow in the career path of another former commissioner, Scott Gottlieb.

Pandemic Perspectives: How COVID Emergency Use Authorizations Could Reshape US FDA

From re-examining the FDA’s place in the broader US government to how fast and flexible it can be clearing therapies in non-emergency times, the COVID-19 EUA experience is expected to have a long-lasting impact on the agency. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS143079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel